tiprankstipranks
Trending News
More News >
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
US Market

Amylyx Pharmaceuticals Inc (AMLX) Stock Forecast & Price Target

Compare
547 Followers
See the Price Targets and Ratings of:

AMLX Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Amylyx
Pharmaceuticals Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AMLX Stock 12 Month Forecast

Average Price Target

$11.00
▲(102.95%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Amylyx Pharmaceuticals Inc in the last 3 months. The average price target is $11.00 with a high forecast of $16.00 and a low forecast of $8.00. The average price target represents a 102.95% change from the last price of $5.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.938461538461538,6.776923076923077,7.615384615384615,8.453846153846154,9.292307692307691,10.13076923076923,10.96923076923077,11.807692307692307,12.646153846153846,13.484615384615385,14.323076923076924,15.161538461538461,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.553846153846154,6.007692307692308,6.461538461538462,6.915384615384616,7.36923076923077,7.823076923076923,8.276923076923076,8.73076923076923,9.184615384615384,9.638461538461538,10.092307692307692,10.546153846153846,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.323076923076923,5.546153846153846,5.769230769230769,5.992307692307692,6.2153846153846155,6.438461538461539,6.661538461538461,6.884615384615385,7.107692307692307,7.330769230769231,7.553846153846154,7.776923076923077,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.71,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$11.00Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AMLX
TipRanks AITipRanks
Not Ranked
TipRanks
$6
Hold
10.70%
Upside
Reiterated
06/11/25
Amylyx Pharmaceuticals displays a mixed outlook. The company's financial performance presents significant challenges with declining revenues and negative profitability. However, positive technical indicators and a promising earnings call with clinical advancements provide some optimism. Valuation remains a concern due to negative earnings, underscoring the need for careful monitoring of financial health and operational progress.
H.C. Wainwright Analyst forecast on AMLX
Andrew FeinH.C. Wainwright
H.C. Wainwright
$16
Buy
195.20%
Upside
Reiterated
06/11/25
Optimistic Buy Rating for Amylyx Pharmaceuticals' AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights
TD Cowen Analyst forecast on AMLX
Joseph ThomeTD Cowen
TD Cowen
Buy
Initiated
05/30/25
Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from TD Cowen
Bank of America Securities Analyst forecast on AMLX
Charlie CY YangBank of America Securities
Bank of America Securities
$10
Buy
84.50%
Upside
Reiterated
05/14/25
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Bank of America Securities
Mizuho Securities Analyst forecast on AMLX
Graig SuvannavejhMizuho Securities
Mizuho Securities
$7$8
Buy
47.60%
Upside
Reiterated
05/14/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on AMLX
Marc GoodmanLeerink Partners
Leerink Partners
$4$10
Buy
84.50%
Upside
Reiterated
05/09/25
Amylyx upgraded to Outperform from Market Perform at LeerinkAmylyx upgraded to Outperform from Market Perform at Leerink
Goldman Sachs Analyst forecast on AMLX
Corinne JohnsonGoldman Sachs
Goldman Sachs
$5
Hold
-7.75%
Downside
Reiterated
11/21/24
Goldman Sachs reiterates Neutral Rating on Amylyx Pharmaceuticals inc. (AMLX)Goldman Sachs analyst Corinne Jenkins reiterated a Neutral rating and $5.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX)
Robert W. Baird Analyst forecast on AMLX
Joel BeattyRobert W. Baird
Robert W. Baird
$3$11
Buy
102.95%
Upside
Upgraded
11/18/24
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AMLX
TipRanks AITipRanks
Not Ranked
TipRanks
$6
Hold
10.70%
Upside
Reiterated
06/11/25
Amylyx Pharmaceuticals displays a mixed outlook. The company's financial performance presents significant challenges with declining revenues and negative profitability. However, positive technical indicators and a promising earnings call with clinical advancements provide some optimism. Valuation remains a concern due to negative earnings, underscoring the need for careful monitoring of financial health and operational progress.
H.C. Wainwright Analyst forecast on AMLX
Andrew FeinH.C. Wainwright
H.C. Wainwright
$16
Buy
195.20%
Upside
Reiterated
06/11/25
Optimistic Buy Rating for Amylyx Pharmaceuticals' AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights
TD Cowen Analyst forecast on AMLX
Joseph ThomeTD Cowen
TD Cowen
Buy
Initiated
05/30/25
Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from TD Cowen
Bank of America Securities Analyst forecast on AMLX
Charlie CY YangBank of America Securities
Bank of America Securities
$10
Buy
84.50%
Upside
Reiterated
05/14/25
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Bank of America Securities
Mizuho Securities Analyst forecast on AMLX
Graig SuvannavejhMizuho Securities
Mizuho Securities
$7$8
Buy
47.60%
Upside
Reiterated
05/14/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on AMLX
Marc GoodmanLeerink Partners
Leerink Partners
$4$10
Buy
84.50%
Upside
Reiterated
05/09/25
Amylyx upgraded to Outperform from Market Perform at LeerinkAmylyx upgraded to Outperform from Market Perform at Leerink
Goldman Sachs Analyst forecast on AMLX
Corinne JohnsonGoldman Sachs
Goldman Sachs
$5
Hold
-7.75%
Downside
Reiterated
11/21/24
Goldman Sachs reiterates Neutral Rating on Amylyx Pharmaceuticals inc. (AMLX)Goldman Sachs analyst Corinne Jenkins reiterated a Neutral rating and $5.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX)
Robert W. Baird Analyst forecast on AMLX
Joel BeattyRobert W. Baird
Robert W. Baird
$3$11
Buy
102.95%
Upside
Upgraded
11/18/24
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amylyx Pharmaceuticals Inc

1 Month
xxx
Success Rate
8/16 ratings generated profit
50%
Average Return
-0.34%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.34% per trade.
3 Months
xxx
Success Rate
9/16 ratings generated profit
56%
Average Return
+20.53%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +20.53% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
10/18 ratings generated profit
56%
Average Return
+18.83%
reiterated a buy rating 2 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +18.83% per trade.
2 Years
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+31.37%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +31.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMLX Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
5
4
4
8
8
Buy
0
0
0
1
1
Hold
2
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
5
5
10
9
In the current month, AMLX has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AMLX average Analyst price target in the past 3 months is 11.00.
Each month's total comprises the sum of three months' worth of ratings.

AMLX Financial Forecast

AMLX Earnings Forecast

Next quarter’s earnings estimate for AMLX is -$0.44 with a range of -$0.47 to -$0.39. The previous quarter’s EPS was -$0.42. AMLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.
Next quarter’s earnings estimate for AMLX is -$0.44 with a range of -$0.47 to -$0.39. The previous quarter’s EPS was -$0.42. AMLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.

AMLX Sales Forecast

Next quarter’s sales forecast for AMLX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.
Next quarter’s sales forecast for AMLX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.

AMLX Stock Forecast FAQ

What is AMLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Amylyx Pharmaceuticals Inc’s 12-month average price target is 11.00.
    What is AMLX’s upside potential, based on the analysts’ average price target?
    Amylyx Pharmaceuticals Inc has 102.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AMLX a Buy, Sell or Hold?
          Amylyx Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Amylyx Pharmaceuticals Inc’s price target?
            The average price target for Amylyx Pharmaceuticals Inc is 11.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $8.00. The average price target represents 102.95% Increase from the current price of $5.42.
              What do analysts say about Amylyx Pharmaceuticals Inc?
              Amylyx Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of AMLX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis